Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL878386 | 0.91 | RPS6KB1 (0.34) | KDM4EMEN1POLBMAPTRECQL | |
| SCHEMBL871103 | 0.88 | KDM4E (0.33) | KDM4EMEN1POLBMAPTRECQL | |
| SCHEMBL870673 | 0.88 | CA1 (0.34) | MAPTPDK2NPC1 | |
| SCHEMBL870580 | 0.88 | KDM4E (0.35) | KDM4EMEN1POLBMAPTRECQL | |
| SCHEMBL872468 | 0.86 | CA1 (0.32) | — | |
| SCHEMBL871766 | 0.86 | KDM4E (0.33) | KDM4EMEN1POLBMAPTRECQL | |
| SCHEMBL869751 | 0.85 | KDM4E (0.35) | KDM4EMEN1POLBMAPTRECQL | |
| SCHEMBL869976 | 0.85 | KDM4E (0.35) | KDM4EMEN1POLBMAPTRECQL | |
| SCHEMBL871009 | 0.81 | ALOX5AP (0.35) | MEN1KMT2AALDH1A1PDK2 | |
| SCHEMBL870589 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077765-A1 | ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS | CYP1A2, CYP3A7, CYP2E1 | KDM4E 3050/4885MEN1 3815/4885POLB 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.